RxDoctor Payments Data

Yuji Saito, MD

Clinical Cardiac Electrophysiology · Salinas, CANPI 1124176110

Payments from drug & device makers

$42,208in general payments, 2019–2025

Across 1,170 payments — averaging $36.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$17K
  • Boston Scientific$13K
  • Abbott$7K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$999
  • Biosense Webster, Inc.$663
  • Novartis$463
  • plus $3K from 31 others

What the payments were for

  • Consulting fees$6752%
  • Travel & lodging$11,51337%
  • Food & beverage$19,04961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,208 in reported general payments places this provider in the 50th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$474,962
Medicare patients
1,733
Services billed
6,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban413$510,331
XareltoRivaroxaban183$252,895
EntrestoSacubitril/Valsartan59$66,061
JardianceEmpagliflozin12$18,747
Amiodarone Hcl260$7,968
Metoprolol Succinate358$5,246
Flecainide Acetate76$5,206
Carvedilol275$3,414
Losartan Potassium239$2,177
Warfarin Sodium130$1,716
Atorvastatin Calcium146$1,600
Diltiazem 24hr Er (Cd)Diltiazem Hcl49$1,510
Amlodipine Besylate184$1,442
Isosorbide Mononitrate ErIsosorbide Mononitrate65$1,355
Diltiazem 24hr ErDiltiazem Hcl23$1,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$175$510,331413 claims
Johnson & JohnsonXarelto$330$252,895183 claims
NovartisEntresto$463$66,06159 claims
Boehringer IngelheimJardiance$169$18,74712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →